First Trust Advisors LP Sells 82,922 Shares of Genmab A/S Sponsored ADR $GMAB

First Trust Advisors LP trimmed its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 4.7% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,687,388 shares of the company’s stock after selling 82,922 shares during the quarter. First Trust Advisors LP’s holdings in Genmab A/S were worth $51,752,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Pitcairn Co. boosted its position in Genmab A/S by 34.8% during the 3rd quarter. Pitcairn Co. now owns 16,535 shares of the company’s stock valued at $507,000 after acquiring an additional 4,269 shares in the last quarter. Orion Porfolio Solutions LLC raised its position in shares of Genmab A/S by 2.3% in the 3rd quarter. Orion Porfolio Solutions LLC now owns 19,693 shares of the company’s stock worth $604,000 after acquiring an additional 441 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Genmab A/S by 6.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 56,330 shares of the company’s stock worth $1,728,000 after purchasing an additional 3,225 shares during the last quarter. Level Four Advisory Services LLC boosted its position in Genmab A/S by 3.7% during the third quarter. Level Four Advisory Services LLC now owns 67,343 shares of the company’s stock valued at $2,065,000 after purchasing an additional 2,418 shares in the last quarter. Finally, Choreo LLC grew its stake in Genmab A/S by 13.8% in the third quarter. Choreo LLC now owns 29,363 shares of the company’s stock valued at $901,000 after purchasing an additional 3,569 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Down 2.1%

NASDAQ:GMAB opened at $27.38 on Thursday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The company’s fifty day moving average price is $31.13 and its 200-day moving average price is $30.47. Genmab A/S Sponsored ADR has a 1-year low of $17.24 and a 1-year high of $35.43. The firm has a market capitalization of $17.59 billion, a P/E ratio of 17.66, a PEG ratio of 1.15 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. As a group, equities research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on GMAB shares. Guggenheim decreased their price target on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, February 23rd. HC Wainwright lifted their price objective on shares of Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Jefferies Financial Group began coverage on shares of Genmab A/S in a research report on Tuesday, February 17th. They set a “buy” rating and a $41.50 target price for the company. Finally, Morgan Stanley assumed coverage on shares of Genmab A/S in a report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price target on the stock. Six analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.58.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.